Your browser doesn't support javascript.
loading
Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.
Theunissen, Peter T; Beken, Sonja; Beyer, Bruce K; Breslin, William J; Cappon, Gregg D; Chen, Connie L; Chmielewski, Gary; De Schaepdrijver, Luc; Enright, Brian; Foreman, Jennifer E; Harrouk, Wafa; Hew, Kok-Wah; Hoberman, Alan M; Hui, Julia Y; Knudsen, Thomas B; Laffan, Susan B; Makris, Susan L; Martin, Matt; McNerney, Mary Ellen; Siezen, Christine L; Stanislaus, Dinesh J; Stewart, Jane; Thompson, Kary E; Tornesi, Belen; Van der Laan, Jan Willem; Weinbauer, Gerhard F; Wood, Sandra; Piersma, Aldert H.
Afiliación
  • Theunissen PT; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
  • Beken S; b Medicines Evaluation Board , Utrecht , The Netherlands.
  • Beyer BK; c Innovative Testing in Life Sciences and Chemistry, University of Applied Sciences Utrecht (HU) , Utrecht , The Netherlands.
  • Breslin WJ; d Federal Agency for Medicines and Health Products , Brussels , Belgium.
  • Cappon GD; e Sanofi U.S. Inc. Bridgewater , NJ , USA.
  • Chen CL; f Lilly Research Laboratories , Lilly Corporate Center , Indianapolis , IN , USA.
  • Chmielewski G; g Pfizer Worldwide Research & Development , Groton , CT , USA.
  • De Schaepdrijver L; h ILSI-Health and Environmental Sciences Institute , Washington , DC , USA.
  • Enright B; i Covance Laboratories Inc , Greenfield , IN , USA.
  • Foreman JE; j Janssen R&D, Preclinical Development & Safety Beerse , Belgium.
  • Harrouk W; k AbbVie Inc , North Chicago , IL , USA.
  • Hew KW; l ExxonMobil Biomedical Sciences, Inc , Annandale , NJ , USA.
  • Hoberman AM; m U.S. Food & Drug Administration , Silver Spring , MD , USA.
  • Hui JY; n Takeda Pharmaceutical Company , Deerfield , IL , USA.
  • Knudsen TB; o Charles-River Laboratories, Preclinical Services , Horsham , PA , USA.
  • Laffan SB; p Celgene Corporation , Summit , NJ , USA.
  • Makris SL; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA.
  • Martin M; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA.
  • McNerney ME; s U.S. Environmental Protection Agency, National Center for Environmental Assessment , Washington , DC , USA.
  • Siezen CL; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA.
  • Stanislaus DJ; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA.
  • Stewart J; b Medicines Evaluation Board , Utrecht , The Netherlands.
  • Thompson KE; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA.
  • Tornesi B; u Drug Safety & Metabolism, AstraZeneca , Macclesfield , UK.
  • Van der Laan JW; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA.
  • Weinbauer GF; k AbbVie Inc , North Chicago , IL , USA.
  • Wood S; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.
  • Piersma AH; b Medicines Evaluation Board , Utrecht , The Netherlands.
Crit Rev Toxicol ; 46(10): 900-910, 2016 11.
Article en En | MEDLINE | ID: mdl-27848393
ABSTRACT
Regulatory non-clinical safety testing of human pharmaceuticals typically requires embryo-fetal developmental toxicity (EFDT) testing in two species (one rodent and one non-rodent). The question has been raised whether under some conditions EFDT testing could be limited to one species, or whether the testing in a second species could be decided on a case-by-case basis. As part of a consortium initiative, we built and queried a database of 379 compounds with EFDT studies (in both rat and rabbit animal models) conducted for marketed and non-marketed pharmaceuticals for their potential for adverse developmental and maternal outcomes, including EFDT incidence and the nature and severity of adverse findings. Manifestation of EFDT in either one or both species was demonstrated for 282 compounds (74%). EFDT was detected in only one species (rat or rabbit) in almost a third (31%, 118 compounds), with 58% (68 compounds) of rat studies and 42% (50 compounds) of rabbit studies identifying an EFDT signal. For 24 compounds (6%), fetal malformations were observed in one species (rat or rabbit) in the absence of any EFDT in the second species. In general, growth retardation, fetal variations, and malformations were more prominent in the rat, whereas embryo-fetal death was observed more often in the rabbit. Discordance across species may be attributed to factors such as maternal toxicity, study design differences, pharmacokinetic differences, and pharmacologic relevance of species. The current analysis suggests that in general both species are equally sensitive on the basis of an overall EFDT LOAEL comparison, but selective EFDT toxicity in one species is not uncommon. Also, there appear to be species differences in the prevalence of various EFDT manifestations (i.e. embryo-fetal death, growth retardation, and dysmorphogenesis) between rat and rabbit, suggesting that the use of both species has a higher probability of detecting developmental toxicants than either one alone.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Teratógenos / Sustancias Peligrosas / Modelos Animales / Desarrollo Fetal / Pruebas de Mutagenicidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Crit Rev Toxicol Asunto de la revista: TOXICOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Teratógenos / Sustancias Peligrosas / Modelos Animales / Desarrollo Fetal / Pruebas de Mutagenicidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Crit Rev Toxicol Asunto de la revista: TOXICOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos